[go: up one dir, main page]

WO2001040277A3 - Carbohydrate-aminated glycoproteins - Google Patents

Carbohydrate-aminated glycoproteins Download PDF

Info

Publication number
WO2001040277A3
WO2001040277A3 PCT/US2000/033075 US0033075W WO0140277A3 WO 2001040277 A3 WO2001040277 A3 WO 2001040277A3 US 0033075 W US0033075 W US 0033075W WO 0140277 A3 WO0140277 A3 WO 0140277A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbohydrate
aminated
subject
glycoproteins
relates
Prior art date
Application number
PCT/US2000/033075
Other languages
French (fr)
Other versions
WO2001040277A2 (en
Inventor
Leslie W Fisette
Bernard Malfroy-Camine
Original Assignee
Eukarion Inc
Leslie W Fisette
Bernard Malfroy-Camine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eukarion Inc, Leslie W Fisette, Bernard Malfroy-Camine filed Critical Eukarion Inc
Priority to AU20642/01A priority Critical patent/AU2064201A/en
Publication of WO2001040277A2 publication Critical patent/WO2001040277A2/en
Publication of WO2001040277A3 publication Critical patent/WO2001040277A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to carbohydrate-aminated glycoproteins (e.g., antibodies, growth factors) which comprise a diamine moiety which is covalently bonded to a carbohydrate moiety through a single or double bond that is formed between a nitrogen atom of said diamine moiety and a carbon atom of an oxidized carbohydrate moiety of said glycoprotein, and to pharmaceutical compositions comprising the carbohydrate-aminated glycoproteins. The carbohydrate-aminated glycoproteins of the invention can traverse the plasma membrane of living cells and are taken up by organs and tissues more rapidly and to a greater extent than native glycoproteins after intravascular administration. The invention also relates to a method of intracellularly delivering a carbohydrate-aminated glycoprotein to a cell, and to a method of transvascularly delivering a carbohydrate-aminated glycoprotein to an organ or tissue. The invention also relates to a method of inhibiting the replication of a virus in a subject, comprising administering to the subject a carbohydrate-aminated antibody which inhibits replication of the virus by, for example, binding to a protein necessary for replication. The invention also relates to a method of treating a subject infected with an intracellular parasite, comprising administering to the subject a carbohydrate-aminated antibody which inhibits proliferation and/or spread of the parasite by, for example, binding to a protein which functions in proliferation or spread of the parasite. The invention further relates to a method of treating a subject having a tumor, comprising administering to the subject a carbohydrate-aminated antibody which is directed against a tumor antigen.
PCT/US2000/033075 1999-12-06 2000-12-06 Carbohydrate-aminated glycoproteins WO2001040277A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20642/01A AU2064201A (en) 1999-12-06 2000-12-06 Carbohydrate-aminated glycoproteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45559899A 1999-12-06 1999-12-06
US09/455,598 1999-12-06

Publications (2)

Publication Number Publication Date
WO2001040277A2 WO2001040277A2 (en) 2001-06-07
WO2001040277A3 true WO2001040277A3 (en) 2002-06-27

Family

ID=23809488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033075 WO2001040277A2 (en) 1999-12-06 2000-12-06 Carbohydrate-aminated glycoproteins

Country Status (2)

Country Link
AU (1) AU2064201A (en)
WO (1) WO2001040277A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
MX347611B (en) 2011-06-19 2017-05-04 Abogen Inc DEVICES, SOLUTIONS AND METHODS FOR SAMPLE COLLECTION.
JP2017510284A (en) * 2014-04-10 2017-04-13 ディーエヌエー ジェノテック インク Method and system for microbial lysis using periodate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237479A1 (en) * 1992-11-06 1994-05-11 Behringwerke Ag Process for the production of conjugates from a specific binding partner and a carbohydrate-containing protein
WO1996029094A1 (en) * 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237479A1 (en) * 1992-11-06 1994-05-11 Behringwerke Ag Process for the production of conjugates from a specific binding partner and a carbohydrate-containing protein
WO1996029094A1 (en) * 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents

Also Published As

Publication number Publication date
AU2064201A (en) 2001-06-12
WO2001040277A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
Aquilante et al. Increased brain P-glycoprotein in morphine tolerant rats
DE69535519T2 (en) ON YEAST BASED VEHICLES FOR DELIVERY
Pinsky et al. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta.
EP0374207B1 (en) Drug for treating cancer, aids and viral diseases
MD1444B2 (en) Methods for inducing T cells tolerance to donor tissues or organs
JPH05504554A (en) Methods and compositions for promoting immune enhancement
Human et al. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration?
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
JP2008526749A (en) Sustained release delivery of PDGF using self-assembling peptide nanofibers
EP1027073A2 (en) Enhanced effects for hapten conjugated therapeutics
EP1090924A4 (en) PEPTIDES OF TUMOR ANTIGENS FROM CYCLOPHILIN B
DE69610295T3 (en) PHARMACEUTICAL COMPOSITIONS DERIVED FROM A RETROVIRAL REGULATORY PROTEIN, DETOXIFIED IMMUNOGENS, ANTIBODIES PROVIDED THEREFOR, METHODS FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH IMMUNOGENS OR ANTIBODIES.
Su et al. New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Wang et al. Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity
Miettinen et al. Leiomyosarcoma of the mandible: diagnosis as aided by immunohistochemical demonstration of desmin and laminin
US10925960B2 (en) Antigen delivery system
Vesely et al. Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers
EP1455766B1 (en) Thymosin alpha 1 peptide/polymer conjugates
WO2001040277A3 (en) Carbohydrate-aminated glycoproteins
US20240207436A1 (en) Preparation method and application of biomimetic nano-protectant for detoxifying dox-induced cardiac and systemic toxicity
CN106232134B (en) Pleurotoxin, functionally related variants thereof, extracts comprising same and uses thereof
GB0102145D0 (en) Substances
Fiume et al. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat
US20100316624A1 (en) Treatment of fibroses and liver disorders
KR101761092B1 (en) Composition for Transplanting of Islet Cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP